Software provider Blackbaud, Inc. (NASDAQ: BLKB) made a negative pre-announcement Monday after the close, lowering its non-GAAP revenue, operating margin, EPS as well as free cash flow guidance for 2018.
Stifel analyst Tom Roderick downgraded shares of Blackbaud from Buy to Hold and lowered the price target from $120 to $88.
Raymond James analyst Brian Peterson downgraded Blackbaud from Outperform to Market Perform.
Stifel: Lower Guidance Puts Stock In Holding Pattern
The shortfall in Blackbaud's subscription revenue is surprising given the company's Q2 commentary that highlighted record bookings, Stifel's Roderick said in a Monday note.
This is notwithstanding ongoing challenges that are already known, such as top-line pressures due to the services business transitioning toward partners and weakness in U.K.-related payments.
The downward guidance adjustment is due to a reduction in one-time services related to the model transition to cloud; a reduction in transactional and payments-related revenue; and reduced expectations for subscription-based recurring revenue, the analyst said.
"However, model transitions can also mask fundamental challenges, and when those do emerge, it likely takes several quarters to turn the ship back in a more positive direction," Roderick said.
The investments required to execute on faith-based, education and health care initiatives are likely to depress earnings in 2019, the analyst said.
The guidance reset is likely to keep the stock in a new, lower holding pattern for two to three quarters, according to Stifel.
No Near-Term Upside In Raymond James' Forecast
A combination of slowing services and payments revenue, recent changes to sales compensation plans and accelerated sales hiring efforts will ding Blackbaud's subscription growth and margin trends in the next several quarters, Raymond James' Peterson said in a Tuesday downgrade note.
The analyst said he remains positive on Blackbaud's ability to monetize its dominant position in the $8-billion nonprofit software market.
"While shares could still offer attractive returns to more patient investors willing to invest on this reset, we don't believe we'll see a material move to the upside in the near-term."
The Price Action
Blackbaud shares were falling 11.52 percent to $79.64 at the time of publication Tuesday.
Tableau Software Revenue Could Exceed B In Revenue By 2022, KeyBanc Says In Upgrade
Latest Ratings for BLKB
|Oct 2018||DA Davidson||Maintains||Neutral||Neutral|
|Oct 2018||JMP Securities||Downgrades||Market Outperform||Market Perform|
|Oct 2018||Raymond James||Downgrades||Outperform||Market Perform|
View More Analyst Ratings for BLKB
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial
- Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade
- Beacon Roofing On Shaky Foundation As Analyst's Survey Points To Softness
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.